I’d like to focus this month’s blog post on a discussion of cutaneous neurofibromas, which are benign tumors that can grow on nerves throughout the body in some individuals with NF1. Typically ...
WAYNE, Pa., May 26, 2021 /PRNewswire/ — NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for rare disorders driven by aberrant ...
WAYNE, Pa.--(BUSINESS WIRE)--NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare RASopathies, today announced that the Food ...
Please provide your email address to receive an email when new articles are posted on . Small cNFs were successfully reduced with four different nonsurgical treatment modalities. Deoxycholate and ...
UCLA researchers developed a new method to study NF1, accelerating the search for potential treatments. Future work is supported by $1.6 million in grants from the Neurofibromatosis Therapeutics ...
BOSTON, Nov. 13, 2023 /PRNewswire/ -- NFlection Therapeutics Inc., a company developing topical MEK inhibitors for RAS-mediated skin conditions, today announced positive topline results from a ...
In the opinion of R. Rox Anderson, MD, patients with neurofibromatosis type 1 (NF1) have long been underserved in the medical field. Affected children are born with café-au-lait spots and sometimes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback